glp-1 generics in the US are losing ground without disappearing GLP-1 generics surge: Experts warn

Diabetes is also an established and major risk factor for the development and progression of chronic kidney disease (CKD)

Some people prefer caffeinated coffee

According to the Phase 3b, double-blind, placebo-controlled STRIDE study, Ozempic (1 mg) resulted in a superior and clinically meaningful improvement of 13% in maximum walking distance and a mean treatment difference of 39.9 meters on a steep incline compared to placebo at week 52 in adults with T2DM and PAD. If approved, Ozempic will be the only GLP-1 receptor agonist indicated for the treatment of PAD in patients with T2DM

Using such substances without medical supervision can pose significant health risks

Utilize tools such as Continuous Glucose Monitors (CGMs) for real-time feedback

Address gut health: If microbial markers are elevated, targeted gut support may be an important first step in improving cognitive and mood symptoms